Acasti Pharma (ACST) Lifted to Buy at ValuEngine
ValuEngine upgraded shares of Acasti Pharma (NASDAQ:ACST) from a hold rating to a buy rating in a research note released on Wednesday morning.
Shares of NASDAQ ACST opened at $1.00 on Wednesday. The company has a market capitalization of $41.82 million, a P/E ratio of -1.32 and a beta of 1.40. Acasti Pharma has a 12-month low of $0.43 and a 12-month high of $3.36. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.35 and a current ratio of 1.35.
Acasti Pharma (NASDAQ:ACST) last announced its quarterly earnings results on Tuesday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter. On average, research analysts forecast that Acasti Pharma will post -0.7 earnings per share for the current year.
Acasti Pharma Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia.
Recommended Story: What Is An Exchange-Traded Fund (ETF)?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.